ENTREMED INC | 1,796 Euro | +0,090 +5,28 % | |
| WKN: A1C07N ISIN: US29382F2020 Ticker-Symbol: ENMN | Frankfurt | 10.02.12 | 08:02 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 06.02. | EntreMed jumps financing, board change | 3 | MarketWatch | |
| 06.02. | EntreMed (ENMD) Enters $9.3M of Strategic Financing, Two Board Members Resign | 3 | StreetInsider.com | |
| 06.02. | EntreMed Completes Strategic Financing | 11 | PR Newswire | |
| ROCKVILLE, Md., Feb. 6, 2012 /PRNewswire/ --EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today... Mehr lesen zu: EntreMed Completes Strategic Financing | ||||
| 06.02. | Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors | 8 | PR Newswire | |
| ROCKVILLE, Md., Feb. 6, 2012 /PRNewswire/ --EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that Wei-Wu... Mehr lesen zu: Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors | ||||
| 26.01. | EntreMed rallies in wake of Celgene deal | 14 | MarketWatch | |
| 23.01. | EntreMed (ENMD) Enters $10M in Purchase Agreements; Will Issue Convertible Notes | 4 | StreetInsider.com | |
| 23.01. | EntreMed Secures $10 Million Strategic Financing | 22 | PR Newswire | |
| ROCKVILLE, Md., Jan. 23, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has... Mehr lesen zu: EntreMed Secures $10 Million Strategic Financing | ||||
| 14.11. | EntreMed Reports Third Quarter 2011 Financial Results | 11 | PR Newswire | |
| ROCKVILLE, Md., Nov. 14, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results... Mehr lesen zu: EntreMed Reports Third Quarter 2011 Financial Results | ||||
| 03.10. | EntreMed (ENMD) Reports Overall Survival Not Reached in ENMD-2076 Phase 2 | 2 | StreetInsider.com | |
| 03.10. | EntreMed's ENMD-2076 Demonstrates Promising Activity in a Phase 2 Study in Platinum-Resistant Ovarian Cancer Patients | 10 | PR Newswire | |
| ROCKVILLE, Md., Oct. 3, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data... Mehr lesen zu: EntreMed's ENMD-2076 Demonstrates Promising Activity in a Phase 2 Study in Platinum-Resistant Ovarian Cancer Patients | ||||
| Unternehmen / Aktien | Branche | Aktienkurs | Top-Nachrichten | |
|---|---|---|---|---|
| STEMCELLS INC | Biotechnologie | -2,34 % | Hot Stock: StemCells, Shares Gain 7.0% | |
| GERON CORPORATION | Biotechnologie | -2,56 % | Buy, Sell, or Hold: Geron | |
| CURIS INC | Biotechnologie | -3,07 % | Curis Swings To Q4 Profit | |
| AGENUS INC | Biotechnologie | +2,16 % | Antigenics has the Lowest EPS Growth in the Biotechnology Industry | |
| VICAL | Biotechnologie | -4,23 % | Charting Vical's Latest Earnings Release |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
